of afatinib in combination with docetaxel in patients with advanced solid tumors, known to express EGFR/HER2, who had progressed following prior standard therapies. The study defined the MTD of ...

and second-generation (afatinib, dacomitinib) TKIs and with the treatment of resistant disease. Subgroup of EGFR mutated 42 84.6 vs 37.5 (p = 0.002) 8.0 vs 6.3,HR: 0.544, p = 0.086 27.2 vs 25.6 HR ...

These changes, such as mutations in the epidermal growth factor receptor (EGFR), provide specific targets ... such as in the ...